Bupropion for Smoking Cessation in African American light Smokers: A randomized controlled trial

Journal of the National Cancer Institute

Volumn 104, Issue 4, 2012, Pages 290-298

  Cox, Lisa Sanderson ^a,c   Nollen, Nicole L ^a,c   Mayo, Matthew S ^b,c   Choi, Won S ^a,c   Faseru, Babalola ^a,c   Benowitz, Neal L ^d   Tyndale, Rachel F ^e   Okuyemi, Kolawole S ^f   Ahluwalia, Jasjit S ^f,g  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g University of Minnesota Medical School ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; COTININE; PLACEBO;

ADULT; AFRICAN AMERICAN; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; THERAPY EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AFRICAN AMERICANS; AGED; BIOLOGICAL MARKERS; BUPROPION; COTININE; DEPRESSION; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; SALIVA; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; UNITED STATES;

EID: 84857614596     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr513     Document Type: Article

References (45)

1. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society; 2009.
2. Trinidad DR, Perez-Stable EJ, Emery SL, White MM, Grana RA, Messer KS. Intermittent and light daily smoking across racial/ethnic groups in the United States. Nicotine Tob Res. 2009; 11 (2): 203-210.
3. Schoenborn CA, Adams PF, Barnes PM, Vickerie JL, Schiller JS. Health behaviors of adults: United States, 1999-2001. Vital Health Stat 10. 2004; 219: 1-79.
4. CDC. Cigarette smoking among adults and trends in smoking cessation-United States, 2008. MMWR Morb Mortal Wkly Rep. 2009; 58 (44): 1227-1232.
5. Fu S, Kodl M, Joseph A, et al. Racial/Ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44 years. Cancer Epidemiol Biomarkers Prev. 2008; 17 (7): 1640-1647.
6. Fagan P, Moolchan ET, Lawrence D, Fernander A, Ponder PK. Identifying health disparities across the tobacco continuum. Addiction. 2007; 102 (suppl 2): 5-29. (Pubitemid 47390243)
7. Cox LS, Okuyemi K, Choi WS, Ahluwalia JS. A review of tobacco use treatments in U.S. ethnic minority populations. Am J Public Health. 2011; 25 (Suppl 5): S11-S30.
8. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA. 2002; 288 (4): 468-474. (Pubitemid 34787478)
9. Ahluwalia JS, Okuyemi K, Nollen N, et al. The effects of nicotine gum and counseling among African American light smokers: a 2 x 2 factorial design. Addiction. 2006; 101 (6): 883-891. (Pubitemid 43727522)
10. Gariti P, Lynch K, Alterman A, Kampman K, Xie H, Varillo K. Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. J Subst Abuse Treat. 2009; 37 (3): 247-255.
11. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008.
12. Allen B Jr, Unger JB. Sociocultural correlates of menthol cigarette smoking among adult African Americans in Los Angeles. Nicotine Tob Res. 2007; 9 (4): 447-451. (Pubitemid 46534456)
13. Castro FG. Physiological, psychological, social, and cultural influences on the use of menthol cigarettes among Blacks and Hispanics. Nicotine Tob Res. 2004; 6 (suppl 1): S29-S41.
14. Ho MK, Mwenifumbo JC, Al Koudsi N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. 2009; 85 (6): 635-643.
15. Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. Am J Epidemiol. 2009; 169 (2): 236-248.
16. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob P. Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther. 1999; 291 (3): 1196-1203.
17. Ho MK, Faseru B, Choi WS, et al. Utility and relationships of biomarkers of smoking in African-American light smokers. Cancer Epidemiol Biomarkers Prev. 2009; 18 (12): 3426-3434.
18. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007; (1): CD000031.
19. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl). 2008; 197 (3): 371-377.
20. Cox LS, Faseru B, Mayo MS, et al. Design, measures, and baseline characteristics from a randomized clinical trial of bupropion in African-American light smokers. Trials. 2011; 12: 22.
21. Okuyemi KS, Cox LS, Nollen NL, et al. Baseline characteristics and recruitment strategies in a randomized clinical trial of African-American light smokers. Am J Health Promot. 2007; 21 (3): 183-191. (Pubitemid 46105392)
22. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991; 86 (9): 1119-1127.
23. Smith SS, Piper ME, Fiore MC, Baker TB. Subscale consolidation and item reduction of the 68 item Wisconsin Inventory of Smoking Dependence Motives (WISDM-68). In: Proceedings of the Society for Research on Nicotine and Tobacco; 21-24 February 2007; Austin, TX.
24. Piper ME, Piasecki TM, Federman EB, et al. A multiple motives approach to tobacco dependence: the Wisconsin Inventory of Smoking Dependence Motives (WISDM-68). J Consult Clin Psychol. 2004; 72 (2): 139-154. (Pubitemid 38393082)
25. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986; 43 (3): 289-294. (Pubitemid 16052281)
26. Radloff LS. The CES-D Scale. Appl Psychol Meas. 1977; 1 (3): 385-401.
27. Cole JC, Rabin AS, Smith TL, Kaufman AS. Development and validation of a Rasch-derived CES-D short form. Psychol Assess. 2004; 16 (4): 360-372. (Pubitemid 39546414)
28. Cohen S, Lichtenstein E. Perceived stress, quitting smoking, and smoking relapse. Health Psychol. 1990; 9 (4): 466-478.
29. Stewart JJ, Berkel HJ, Parish RC, et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol. 2001; 41 (7): 770-778. (Pubitemid 32612441)
30. Benowitz NL, Jacob P III, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther. 1994; 268 (1): 296-303. (Pubitemid 24039102)
31. Benowitz NL, Zevin S, Jacob P III. Sources of variability of nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Br J Clin Pharmacol. 1997; 43 (3): 259-267. (Pubitemid 27116065)
32. Jacob P III, Wilson M, Benowitz NL. Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr. 1981; 222 (1): 61-70. (Pubitemid 11141159)
33. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003; 5 (1): 13-25. (Pubitemid 36285465)
34. Benowitz NL, Jacob P, Ahijevych K, et al. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002; 4 (2): 149-159. (Pubitemid 34679841)
35. Murray RP, Connett JE, Lauger GG, Voelker HT. Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group. Am J Public Health. 1993; 83 (9): 1251-1257. (Pubitemid 23262028)
36. Cummings SR, Richard RJ. Optimum cutoff points for biochemical validation of smoking status. Am J Public Health. 1988; 78 (5): 574-575.
37. SAS/STAT User's Guide [Computer Program]. Version 8. Cary, NC: SAS Institute, Inc.; 1999.
38. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. 2006. http: //ctep.cancer.gov/reporting/ctc.html. Accessed February 1, 2011.
39. Shiffman S. Nicotine lozenge efficacy in light smokers. Drug Alcohol Depend. 2005; 77 (3): 311-314. (Pubitemid 40283533)
40. Baker TB, Piper ME, McCarthy DE, et al. Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tobacco Research. 2007; 9 (suppl 4): S555-S570.
41. Croghan IT, Hurt RD, Dakhil SR, et al. Randomized comparison of nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clinic Proc. 2007; 82 (2): 186-195. (Pubitemid 46198478)
42. Hays JT, Hurt RD, Rigotti NA, et al. Sustained release buproprion for pharmacologic relapse prevention after smoking cessation. Ann Intern Med. 2001; 135 (423-433. (Pubitemid 32845867)
43. Covey LS, Glassman AH, Jiang H, et al. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction. 2007; 102 (8): 1292-1302. (Pubitemid 47037935)
44. Killen JD, Fortmann SP, Murphy GM, et al. Extended treatment with bupropion SR for cigarette smoking cessation. J Consult Clin Psychol. 2006; 74 (2): 286-294. (Pubitemid 43807361)
45. Cox LS, Bronars CA, Thomas JL, et al. Achieving high rates of consent for genetic testing among African American smokers. Nicotine Tob Res. 2007; 9 (6): 711-716. (Pubitemid 46930321)